Genetic Polymorphism of CYP2D6 and MDR1 in breast cancer patients treated with tamoxifen
Introduction: Tamoxifen is the drug of choice for the treatment of breast cancer patients who are positive for estrogen receptor. It is metabolized by Cytochrome P450 2D6 (CYP2D6) and the variations in CYP2D6 activity has been reported to have important therapeutic consequences which include develop...
Main Authors: | Mohamad, NI, Ismail, S, Hamzah , S, Harun, R, Ngow , Harris Abdullah |
---|---|
Format: | Proceeding Paper |
Language: | English |
Published: |
2010
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/5238/1/Abstract_CYP2D6_NNCC.pdf |
Similar Items
-
CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia
by: Ngow, Harris Abdullah, et al.
Published: (2009) -
Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study
by: Ngow, Harris Abdullah, et al.
Published: (2008) -
Lack of correlation between INR and warfarin dose: a role of pharmacogenotyping of CYP2C9*3 and VKORC1 for anticoagulation
by: Salleh, Mohd Zaki, et al.
Published: (2009) -
VKORC1 Haplotypes in patients treated with warfarin
by: Beshna, E, et al.
Published: (2010) -
Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
by: Teh, L. K., et al.
Published: (2011)